ARMS patients without a PAX3/7-FOXO1 translocation have both molecular features and clinical outcome similar to ERMS.1, 2 Therefore, molecular classification as fusion-positive RMS (FP-RMS) and fusion-negative RMS (FN-RMS) based on the presence or absence of the PAX3/7-FOXO1 fusion more accurately represents both the biology and clinical features of RMS. The gene discussed is PAX3; the disease is alveolar rhabdomyosarcoma.